Drugmaker Group Boosts Lobbying as Push to Lower Prices Stalls
- Top companies also report higher spending in second quarter
- Trump has made lowering prescription drug prices a priority
Photographer: Joe Raedle/Getty Images
This article is for subscribers only.
The drug industry’s primary trade group increased its spending on lobbying during the second quarter, as President Donald Trump’s promised efforts to lower the prices of prescription drugs stalled.
The Pharmaceutical Research and Manufacturers of America, which represents leading drugmakers, reported spending $6.2 million in the quarter that ended June 30, a 12% increase from $5.5 million in the same period last year, according to a disclosure filed with Congress by Monday’s deadline. The group reported lobbying on several pieces of legislation that dealt with drug pricing.